These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 25998512

  • 21. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
    Song JL, Wei XL, Zhang YK, Hao XX, Huang WM, Wei Q, Wei YQ, Feng R.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep 14; 39(9):739-744. PubMed ID: 30369184
    [Abstract] [Full Text] [Related]

  • 22. Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.
    Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP.
    Br J Haematol; 2016 Jan 14; 172(2):246-54. PubMed ID: 26577576
    [Abstract] [Full Text] [Related]

  • 23. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI.
    Korean J Intern Med; 2014 Nov 14; 29(6):785-92. PubMed ID: 25378977
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
    Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD.
    J Clin Oncol; 2015 Sep 10; 33(26):2848-56. PubMed ID: 26240231
    [Abstract] [Full Text] [Related]

  • 26. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Lancet; 2013 May 25; 381(9880):1817-26. PubMed ID: 23615461
    [Abstract] [Full Text] [Related]

  • 27. Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy.
    Gomez-Gelvez JC, Salama ME, Perkins SL, Leavitt M, Inamdar KV.
    Am J Clin Pathol; 2016 Apr 25; 145(4):514-23. PubMed ID: 27124945
    [Abstract] [Full Text] [Related]

  • 28. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
    Kim YS, Ji JH, Ko YH, Kim SJ, Kim WS.
    Acta Haematol; 2014 Apr 25; 131(3):156-61. PubMed ID: 24192382
    [Abstract] [Full Text] [Related]

  • 29. Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma.
    Arima H, Maruoka H, Nasu K, Tabata S, Kurata M, Matsushita A, Imai Y, Takahashi T, Ishikawa T.
    Leuk Lymphoma; 2013 Dec 25; 54(12):2645-53. PubMed ID: 23566159
    [Abstract] [Full Text] [Related]

  • 30. Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.
    Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H.
    Eur J Haematol; 2011 Sep 25; 87(3):217-27. PubMed ID: 21575062
    [Abstract] [Full Text] [Related]

  • 31. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB.
    Ann Hematol; 2013 Nov 25; 92(11):1513-20. PubMed ID: 23775580
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wong KK, Ch'ng ES, Loo SK, Husin A, Muruzabal MA, Møller MB, Pedersen LM, Pomposo MP, Gaafar A, Banham AH, Green TM, Lawrie CH.
    Exp Mol Pathol; 2015 Dec 25; 99(3):537-45. PubMed ID: 26341140
    [Abstract] [Full Text] [Related]

  • 34. Metabolic tumour area: a novel prognostic indicator based on 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.
    Cui S, Xin W, Wang F, Shao X, Shao X, Niu R, Zhang F, Shi Y, Liu B, Gu W, Wang Y.
    BMC Cancer; 2024 Jul 25; 24(1):895. PubMed ID: 39054508
    [Abstract] [Full Text] [Related]

  • 35. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
    Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B.
    Ann Hematol; 2014 Aug 25; 93(8):1305-12. PubMed ID: 24590536
    [Abstract] [Full Text] [Related]

  • 36. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M.
    Am J Hematol; 2013 Apr 25; 88(4):273-6. PubMed ID: 23460351
    [Abstract] [Full Text] [Related]

  • 37. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.
    Yoo C, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, Lee DH, Kim SW, Lee JS, Suh C.
    Korean J Intern Med; 2010 Sep 25; 25(3):301-8. PubMed ID: 20830228
    [Abstract] [Full Text] [Related]

  • 38. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X, Xia B, Guo S, Zhan Z, Zhang L, Zhao D, Wu X, Zhang Y.
    Ann Hematol; 2013 Jun 25; 92(6):807-15. PubMed ID: 23417758
    [Abstract] [Full Text] [Related]

  • 39. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients.
    Coutinho R, Lobato J, Esteves S, Cabeçadas J, Gomes da Silva M.
    Ann Hematol; 2019 Aug 25; 98(8):1937-1946. PubMed ID: 30949752
    [Abstract] [Full Text] [Related]

  • 40. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW, Steidl C, Sehn LH, Gascoyne RD.
    Br J Haematol; 2014 Dec 25; 167(5):608-17. PubMed ID: 25135752
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.